The Wnt antagonist, Dickkopf-1, as a target for the treatment of neurodegenerative disorders

Filippo Caraci, Carla Busceti, Francesca Biagioni, Eleonora Aronica, Federica Mastroiacovo, Irene Cappuccio, Giuseppe Battaglia, Valeria Bruno, Andrea Caricasole, Agata Copani, Ferdinando Nicoletti

Research output: Contribution to journalArticlepeer-review


The canonical Wnt pathway contributes to the regulation of neuronal survival and homeostasis in the CNS. Recent evidence suggests that an increased expression of Dickkopf-1 (Dkk-1), a secreted protein that negatively modulates the canonical Wnt pathway, is causally related to processes of neurodegeneration in a number of CNS disorders, including Alzheimer's disease (AD), brain ischemia and temporal lobe epilepsy (TLE). Dkk-1 induction precedes neuronal death in cellular and animal models of excitotoxicity, β-amyloid toxicity, transient global ischemia, and kainate-induced epilepsy. In addition, Dkk-1, which is barely visible in the healthy brain, is strongly induced in brain tissue from AD patients or from patients with TLE associated with hippocampal sclerosis. These data raise the attractive possibility that Dkk-1 antagonists or neutralizing antibodies behave as neuroprotective agents by rescuing the activity of the canonical Wnt pathway.

Original languageEnglish
Pages (from-to)2401-2406
Number of pages6
JournalNeurochemical Research
Issue number12
Publication statusPublished - Dec 2008


  • β-Catenin
  • Canonical Wnt pathway
  • Dkk-1
  • Lithium
  • Neurodegeneration
  • Neuronal death

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'The Wnt antagonist, Dickkopf-1, as a target for the treatment of neurodegenerative disorders'. Together they form a unique fingerprint.

Cite this